NCBiotech News

We work hard to bring you the stories about the life science community in North Carolina. Every once in a while, we add a little news of our own. Read some of those stories below, or check out some of our perspectives on our staff blog.

Heat Biologics, a Durham company developing immunotherapies to fight cancer, has reported positive results from a Phase 1b trial of its combination treatment for non-small cell lung cancer.

The Research Triangle Park-based personalized medicine and clinical nutrition company formerly known as Panacea BioMatx is quickly transforming itself in 2017.

When Heat Biologics licensed the immune system stimulating technology behind its ImPACT and ComPACT platforms from the University of Miami, it also licensed the tech behind Pelican Therapeutics Inc.

Durham-based Heat Biologics Inc. (Nasdaq:HTBX), has inked a deal to acquire an 80 percent controlling interest in Pelican Therapeutics Inc., an immune oncology company based in Austin, Texas.

Durham-based medical device developer Tryton Medical has received U.S. Food and Drug Administration approval to market the company’s Tryton Side Branch Stent for the treatment of coronary bifurcation lesions.

This week at the CED Life Science Conference, Mark McClellan, M.D., director of the Duke-Margolis Center for Health Policy, discussed healthcare reform and biomedical innovation.

The Research Triangle-based AgTech Accelerator launched its first startup, Boragen Inc. with a $10 million Series A financing Thursday.

Entrepreneurs seeking investors in their companies heard from four corporate venture capital funds at the CED Life Science Conference panel, “Follow the Money.”

A panel of experts at the Life Sciences Forum discussed “Value Based Medicine: The Collision of Innovation and Affordability,” Monday at the North Carolina Biotechnology Center.

On the first day of the two-day 2017 CED Life Science Conference, four entrepreneurs with roots at North Carolina State University gathered to provide insight to those seeking to launch a life science startup.

Globally renowned cardiologist Robert Califf knew it was a temp job when he left his Duke faculty position to become FDA commissioner, and he says he's glad to be back home.

Pfizer has committed to providing $4 million to enable the North Carolina Biotechnology Center to establish and administer a  multi-year academic fellowship program to help advance the state's gene therapy expertise.

Charlotte-based HepatoSys has received a $366,000 Phase I grant from the federal Small Business Innovation Research (SBIR) program to fund the research. It will team up with Lonza which acquired Triangle Research Labs of Research Triangle Park in June 2016 to explore HepatoSys’ patented technology for rejuvenating donated human livers that aren’t healthy enough for organ transplants.

Professionals involved in the field of precision medicine will gather May 24 and 25 at Duke University’s Fuqua School of Business in Durham for the Precision Medicine World Conference 2017.

The North Carolina Biotechnology Center has announced that LabCorp Chairman and CEO David P. King will be the keynote speaker for the March 30 Triad BioNight 2017 gala in Greensboro.